Cargando...
Combining neratinib with CDK4/6, mTOR and MEK inhibitors in models of HER2-positive cancer
PURPOSE: Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor that is FDA-approved for HER2-overexpressing/amplified (HER2(+)) breast cancer. In this preclinical study, we explored the efficacy of neratinib in combination with inhibitors of downstream signaling in HER2(+) cancers in vitro...
Guardado en:
| Publicado en: | Clin Cancer Res |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8075007/ https://ncbi.nlm.nih.gov/pubmed/33414137 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-3017 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|